4:56 PM
 | 
Feb 09, 2018
 |  BC Extra  |  Financial News

Biotech index gains erased, fund flows into the red

The return of drug pricing rhetoric and global stock market volatility have rocked biotech indexes over the last two weeks, wiping out most of what had been strong year-to-date gains.

Fund flows into the space have also swung into the red over the same period.

The NASDAQ Biotechnology (NBI) and NYSE Arca Biotech (BTK) indexes and the SPDR S&P Biotech ETF (XBI) exchange-traded fund limped to gains of 0.9%,...

Read the full 330 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >